Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 18280.0
(-0.33%)
KRW 18280.0
(-0.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 20.48 Billion KRW | -15.9% |
| 2022 | 23.18 Billion KRW | -31.63% |
| 2021 | 33.91 Billion KRW | 5.18% |
| 2020 | 32.24 Billion KRW | 45.2% |
| 2019 | 22.2 Billion KRW | -62.71% |
| 2018 | 59.54 Billion KRW | 26.83% |
| 2017 | 46.94 Billion KRW | 11.62% |
| 2016 | 42.05 Billion KRW | 16.94% |
| 2015 | 35.96 Billion KRW | 13.9% |
| 2014 | 31.57 Billion KRW | 4.93% |
| 2013 | 30.09 Billion KRW | 73.78% |
| 2012 | 17.31 Billion KRW | -27.56% |
| 2011 | 23.9 Billion KRW | 8.27% |
| 2010 | 22.08 Billion KRW | 84.0% |
| 2009 | 12 Billion KRW | -4.58% |
| 2008 | 12.57 Billion KRW | -24.74% |
| 2007 | 16.71 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 5.48 Billion KRW | -24.37% |
| 2024 Q2 | 7.36 Billion KRW | 41.6% |
| 2023 Q4 | 7.24 Billion KRW | 40.47% |
| 2023 FY | 19.49 Billion KRW | -15.9% |
| 2023 Q1 | 5.95 Billion KRW | -22.1% |
| 2023 Q2 | 1.95 Billion KRW | -67.17% |
| 2023 Q3 | 5.15 Billion KRW | 164.09% |
| 2022 FY | 23.18 Billion KRW | -31.63% |
| 2022 Q3 | 6.27 Billion KRW | 50.48% |
| 2022 Q4 | 7.63 Billion KRW | 21.66% |
| 2022 Q1 | 5.09 Billion KRW | 227.01% |
| 2022 Q2 | 4.17 Billion KRW | -18.07% |
| 2021 Q2 | 10.03 Billion KRW | 33.74% |
| 2021 Q4 | -4.01 Billion KRW | -119.67% |
| 2021 Q3 | 20.38 Billion KRW | 103.15% |
| 2021 FY | 33.91 Billion KRW | 5.18% |
| 2021 Q1 | 7.5 Billion KRW | 58.13% |
| 2020 FY | 32.24 Billion KRW | 45.2% |
| 2020 Q1 | 10.43 Billion KRW | 138.38% |
| 2020 Q3 | 7.09 Billion KRW | -28.78% |
| 2020 Q4 | 4.74 Billion KRW | -33.14% |
| 2020 Q2 | 9.96 Billion KRW | -4.54% |
| 2019 Q1 | 14.76 Billion KRW | -5.56% |
| 2019 Q2 | 13.94 Billion KRW | -5.56% |
| 2019 Q4 | 4.37 Billion KRW | -62.91% |
| 2019 FY | 22.2 Billion KRW | -62.71% |
| 2019 Q3 | 11.8 Billion KRW | -15.33% |
| 2018 Q4 | 15.63 Billion KRW | 5.41% |
| 2018 FY | 59.54 Billion KRW | 26.83% |
| 2018 Q3 | 14.83 Billion KRW | -2.09% |
| 2018 Q2 | 15.14 Billion KRW | 8.75% |
| 2018 Q1 | 13.92 Billion KRW | 49.72% |
| 2017 Q1 | 11.17 Billion KRW | 29.66% |
| 2017 Q2 | 12.48 Billion KRW | 11.71% |
| 2017 Q3 | 13.97 Billion KRW | 11.93% |
| 2017 FY | 46.94 Billion KRW | 11.62% |
| 2017 Q4 | 9.3 Billion KRW | -33.44% |
| 2016 Q4 | 8.62 Billion KRW | -27.83% |
| 2016 Q1 | 10.67 Billion KRW | 65.77% |
| 2016 FY | 42.05 Billion KRW | 16.94% |
| 2016 Q2 | 10.81 Billion KRW | 1.39% |
| 2016 Q3 | 11.94 Billion KRW | 10.42% |
| 2015 Q4 | 6.43 Billion KRW | -36.66% |
| 2015 Q2 | 10.06 Billion KRW | 8.29% |
| 2015 FY | 35.96 Billion KRW | 13.9% |
| 2015 Q3 | 10.16 Billion KRW | 0.95% |
| 2015 Q1 | 9.29 Billion KRW | 60.52% |
| 2014 Q2 | 8.47 Billion KRW | -8.36% |
| 2014 Q1 | 9.24 Billion KRW | 58.19% |
| 2014 FY | 31.57 Billion KRW | 4.93% |
| 2014 Q4 | 5.79 Billion KRW | -28.2% |
| 2014 Q3 | 8.06 Billion KRW | -4.8% |
| 2013 Q3 | 7.79 Billion KRW | 7.28% |
| 2013 FY | 30.09 Billion KRW | 73.78% |
| 2013 Q2 | 7.26 Billion KRW | -20.83% |
| 2013 Q1 | 9.18 Billion KRW | 88.68% |
| 2013 Q4 | 5.84 Billion KRW | -25.05% |
| 2012 Q1 | 3.36 Billion KRW | 364.35% |
| 2012 Q2 | 3.62 Billion KRW | 7.54% |
| 2012 Q3 | 5.45 Billion KRW | 50.64% |
| 2012 Q4 | 4.86 Billion KRW | -10.85% |
| 2012 FY | 17.31 Billion KRW | -27.56% |
| 2011 Q4 | -1.27 Billion KRW | -128.28% |
| 2011 Q1 | 6.93 Billion KRW | 41.75% |
| 2011 Q2 | 13.73 Billion KRW | 98.02% |
| 2011 FY | 23.9 Billion KRW | 8.27% |
| 2011 Q3 | 4.5 Billion KRW | -67.17% |
| 2010 FY | 22.08 Billion KRW | 84.0% |
| 2010 Q2 | 4.57 Billion KRW | -5.2% |
| 2010 Q3 | 7.79 Billion KRW | 70.47% |
| 2010 Q1 | 4.82 Billion KRW | 903.61% |
| 2010 Q4 | 4.89 Billion KRW | -37.23% |
| 2009 Q3 | 3.2 Billion KRW | -10.03% |
| 2009 Q4 | 480.53 Million KRW | -85.0% |
| 2009 Q1 | 4.75 Billion KRW | 216.0% |
| 2009 FY | 12 Billion KRW | -4.58% |
| 2009 Q2 | 3.55 Billion KRW | -25.18% |
| 2008 Q3 | 2.28 Billion KRW | -44.88% |
| 2008 Q4 | 1.5 Billion KRW | -34.21% |
| 2008 FY | 12.57 Billion KRW | -24.74% |
| 2008 Q1 | 4.63 Billion KRW | 2.43% |
| 2008 Q2 | 4.15 Billion KRW | -10.34% |
| 2007 Q1 | 4.38 Billion KRW | 0.0% |
| 2007 Q3 | 3.86 Billion KRW | -2.12% |
| 2007 Q2 | 3.94 Billion KRW | -9.89% |
| 2007 FY | 16.71 Billion KRW | 0.0% |
| 2007 Q4 | 4.52 Billion KRW | 17.02% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -5519.279% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 73.356% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 125.746% |
| HANDOK Inc. | 12.57 Billion KRW | -62.848% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 1129.808% |
| Yuhan Corporation | 74.56 Billion KRW | 72.527% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -83.248% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 213.534% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 90.891% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -570.287% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -42.744% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -3334.651% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -2025.451% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 24.22% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -5519.279% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 364.108% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -407.839% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 129.284% |
| JW Holdings Corporation | 143.66 Billion KRW | 85.742% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 138.348% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 91.693% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 79.578% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 143.223% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -195.721% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -216.555% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -134.606% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -5519.279% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 57.996% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 84.645% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 79.578% |
| Yuhan Corporation | 74.56 Billion KRW | 72.527% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 2.083% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -557.099% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 52.356% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 79.578% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 62.722% |
| CKD Bio Corp. | -20.15 Billion KRW | 201.647% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 36.449% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 19.041% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 37.02% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 143.223% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 38.201% |
| Boryung Corporation | 68.26 Billion KRW | 69.994% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 154.63% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -42.744% |
| JW Lifescience Corporation | 32.09 Billion KRW | 36.169% |